H Demir1, H Turna, G Can, S Ilvan. 1. Department of Pathology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey. patdrhd1@hotmail.com
Abstract
PURPOSE: recently, molecular subclassification of breast carcinomas has been proposed as a new prognostic parameter. METHODS: we classified 222 invasive breast carcinoma cases in 5 molecular subtypes by using tissue microarray (TMA) and immunohistochemistry methods. These subtypes were luminal A (estrogen receptor/ER and/or progesterone receptor/ PR positive), luminal B (ER and/or PR positive + HER2 positive), HER2-expressing type (ER and PR negative, HER2 positive), basal-like type (ER, PR and HER2 negative, positive with at least one of these myoepithelial markers: CK5/6, CK14, EGFR) and null type (ER, PR, HER2 and myoepithelial markers negative). We compared these subtypes according to their clinicopathological features and GATA3 expression. RESULTS: luminal A was the most frequent subtype. According to overall survival rates, HER2-expressing and basal- like types had the worst prognosis, while luminal A had the best. However, luminal B had the worst prognosis according to disease free survival. Most of the squamous differentiated metaplastic carcinomas were basal-like type. Tubular and mucinous carcinomas were luminal A. Most basal-like tumors were grade III. The majority of grade I tumors were luminal A. GATA3 positivity was associated with low grade tumors and luminal A subtype. CONCLUSION: molecular classification can be accepted as an independent prognostic factor for invasive breast carcinomas. GATA3 expression was associated with luminal A and low histological grade. However, it wasn't shown as an independent parameter.
PURPOSE: recently, molecular subclassification of breast carcinomas has been proposed as a new prognostic parameter. METHODS: we classified 222 invasive breast carcinoma cases in 5 molecular subtypes by using tissue microarray (TMA) and immunohistochemistry methods. These subtypes were luminal A (estrogen receptor/ER and/or progesterone receptor/ PR positive), luminal B (ER and/or PR positive + HER2 positive), HER2-expressing type (ER and PR negative, HER2 positive), basal-like type (ER, PR and HER2 negative, positive with at least one of these myoepithelial markers: CK5/6, CK14, EGFR) and null type (ER, PR, HER2 and myoepithelial markers negative). We compared these subtypes according to their clinicopathological features and GATA3 expression. RESULTS: luminal A was the most frequent subtype. According to overall survival rates, HER2-expressing and basal- like types had the worst prognosis, while luminal A had the best. However, luminal B had the worst prognosis according to disease free survival. Most of the squamous differentiated metaplastic carcinomas were basal-like type. Tubular and mucinous carcinomas were luminal A. Most basal-like tumors were grade III. The majority of grade I tumors were luminal A. GATA3 positivity was associated with low grade tumors and luminal A subtype. CONCLUSION: molecular classification can be accepted as an independent prognostic factor for invasive breast carcinomas. GATA3 expression was associated with luminal A and low histological grade. However, it wasn't shown as an independent parameter.
Authors: Germana Beha; Barbara Brunetti; Pietro Asproni; Luisa Vera Muscatello; Francesca Millanta; Alessandro Poli; Giuseppe Sarli; Cinzia Benazzi Journal: BMC Vet Res Date: 2012-11-12 Impact factor: 2.741
Authors: Naphannop Sereesongsaeng; Sara H McDowell; James F Burrows; Christopher J Scott; Roberta E Burden Journal: Breast Cancer Res Date: 2020-12-09 Impact factor: 6.466
Authors: John A Schmidt; Keith G Danielson; Emily R Duffner; Sara G Radecki; Gerard T Walker; Amber Shelton; Tianjiao Wang; Janice E Knepper Journal: BMC Cancer Date: 2018-07-24 Impact factor: 4.430